BioCentury
ARTICLE | Finance

Vical Inc. (VICL)

April 23, 2001 7:00 AM UTC

Vical(VICL) lost $3.65 (22%) to $13 on 319,900 shares on Friday after announcing on Thursday that it had discontinued a Phase II trial of Leuvectin in patients with metastatic kidney cancer after th...